Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
Total raised: $137M
Investors 5
| Date | Name | Website |
| - | adMare Bio... | admarebio.... |
| - | T1D Fund | t1dfund.or... |
| - | Forbion | forbion.co... |
| - | Genesys Ca... | genesyscap... |
| - | Anges Québ... | angesquebe... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.10.2022 | Series C | $95M | - |
| 08.09.2020 | Series B | $35M | Forbion |
| 25.07.2018 | Series A | $7M | - |
Mentions in press and media 11
| Date | Title | Description |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 17.10.2022 | Inversago Pharma Raises $95 million CAD in Series C Financing | MONTREAL (CANADA) – October 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 mi... |
| 17.10.2022 | Inversago Pharma Raises CAD$95M in Series C Financing | Inversago Pharma, a Montreal, Canada-based clinical stage biotech company, raised CA$95M in Series C funding. The round was led by New Enterprise Associates, with participation from Forbion’s Growth, Amgen Ventures, Forbion Ventures, Fonds ... |
| 17.01.2022 | Inversago Pharma, an adMare Portfolio Company, Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update | MONTREAL, Jan. 17, 2022 –Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder ... |
| 08.09.2020 | Inversago Pharma Closes US$35M Series B Financing Round and Expands Board of Directors | Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it has secured a US$35 million (€32 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidarité... |
| 08.09.2020 | adMare is pleased to increase our investment in Inversago Pharma alongside leading life sciences investors and be a part of building this exceptional Canadian company developing innovative therapies | Inversago Pharma closes US$35M Series B financing round and expands Board of Directors Vancouver and Montreal, Canada – September 8, 2020: Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today anno... |
| 08.09.2020 | Inversago Pharma Closes US$35M Series B Financing Round and Expands Board of Directors | Inversago Pharma Inc. (“Inversago” or “the Company”), the peripheral CB1 blockade company, today announced it has secured a US$35 million (CDN$47 million) Series B financing round led by Forbion, with co-investment from the Fonds de solidar... |
| 08.09.2020 | Inversago Pharma Closes US$35M Series B Financing | Inversago Pharma Inc., a Montreal, Canada-based peripheral CB1 blockade company, secured a US$35m (€32m) Series B financing. The round was led by Forbion, with co-investment from the Fonds de solidarité FTQ, and participation from existing ... |
| 25.07.2018 | Inversago Pharma Receives $7M in Series A Financing | Inversago Pharma, Inc., a Montreal, Canada-based preclinical-stage biotech company, secured a $7m Series A financing. The round was co-led by Genesys Capital and Amorchem, with participation from the JDRF T1D Fund, Accel-Rx, Anges Québec Ca... |
| - | Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion | Novo Nordisk will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio. The deal is Novo Nordisk’s latest attempt to capitalize on the weigh... |
Show more